Novartis Buys US Drugmaker for Up To $665 Million

The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, JERICHO In an up-to-$665 million deal, Novartis is set to acquire Selexys Pharmaceuticals, an inflammatory and thrombotic disease–focused biotech based in Oklahoma City, whose lead candidate, an antibody for the treatment of sickle cell disease–associated pain, has shown promise in a Phase 2 clinical trial, the firms announced this week (November 21). In 2012, Novartis obtained the exclusive right to acquire Selexys and its antibody drug candidate, “SelG1.”

“The acquisition of Selexys by Novartis represents an important step in the continued development of SelG1, a novel, potential first-in-class therapy for patients with this underserved life-threatening disease,” Scott Rollins, former president and chief executive officer of Selexys, said in the statement.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Pairing Protein Engineering and Cellular Assays

Pairing Protein Engineering and Cellular Assays

Lonza
Faster Fluid Measurements for Formulation Development

Meet Honeybun and Breeze Through Viscometry in Formulation Development

Unchained Labs
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo

Products

Metrion Biosciences Logo

Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

Biotium Logo

Biotium Unveils New Assay Kit with Exceptional RNase Detection Sensitivity

Atelerix

Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China

Green Cooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Thermo Fisher Logo